Canadian Cancer Society logo

Bladder cancer

You are here: 

Survival statistics for bladder cancer

Cancer survival statistics are very general estimates and must be interpreted very carefully. Because survival statistics are based on the experience of groups of people in the general population, they cannot be used to predict a particular person’s chances of survival.

There are many different ways to measure and report cancer survival statistics. Your doctor can explain the statistics for bladder cancer and what they mean to you.

Net survival

Net survival represents the probability of surviving cancer in the absence of other causes of death. It is used to give an estimate of the percentage of people who will survive their cancer.

In Canada, the 5-year net survival for bladder cancer is 73%. This means that, on average, about 73% of people diagnosed with bladder cancer will survive for at least 5 years.

Relative survival

Relative survival looks at how likely people with cancer are to survive after their diagnosis compared to people in the general population who do not have cancer, but who share similar characteristics (such as age and sex).

Survival by stage

Survival varies with each stage and grade of bladder cancer. Generally, the earlier bladder cancer is diagnosed and treated, the better the outcome.

Bladder cancer survival
Stage5-year relative survival

0

95%

I

85%

II

55%

III

38%

IV

16%

Questions about survival

Talk to your doctor about your prognosis. A prognosis depends on many factors, including:

  • your health history
  • the type of cancer
  • the stage
  • certain characteristics of the cancer
  • the treatments chosen
  • how the cancer responds to treatment

Only a doctor familiar with these factors can put all of this information together with survival statistics to arrive at a prognosis.

Stories

Dr Troy Harkness Finding new ways to treat drug-resistant cancers

Read more

Clinical trial discovery improves quality of life

Illustration of test tubes

A clinical trial led by the Society’s NCIC Clinical Trials group found that men with prostate cancer who are treated with intermittent courses of hormone therapy live as long as those receiving continuous therapy.

Learn more